Print

Active Biotech AB Year-end Report January - December 2010

2011-02-10

·Laquinimod- positive results presented from ALLEGRO Phase III trial

·TASQ- pivotal Phase III study initiated in the first quarter of 2011

·ANYARA- ongoing Phase III study expected to be concluded in 2012

·57-57- recommended Orphan Medicinal Product Status

·ISI- project proceeding according to plan

·RhuDex(TM)- preparations for continued clinical development in progress

·Net sales SEK 11.4 M (10.8)

·Operating loss SEK 229.0 M (loss: 219.6)

·Loss after tax SEK 221.1 (loss: 224.0)

·Loss per share for the period amounted to 3.38 (loss: 3.81)

·Private placement of SEK 375 M completed after the end of the period

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel. +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB Year-end Report Jan-Dec 2010



Back